-
Pfizer Full Year 2025 Financial Report
Pfizer
Pfizer’s 2025 financial results show a 2% decline in revenue, driven by lower COVID-19 product sales. Non-COVID products and a strong R&D pipeline drive growth. The company projects steady performance with key catalysts in 2026.
-
Global Biopharma Layoffs December 2025
Layoffs
This article tracks recent biotech and pharma layoffs, including major workforce cuts at Voyager Therapeutics, Intercept Pharmaceuticals, Mythic Therapeutics, Pfizer, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
-
-
Pfizer 2025 H1 Report
Financial statements
Pfizer reported $28.4B in revenue for H1 2025, driven by $1.5B in ADC product sales and strong oncology growth. With $13B in BD firepower, Pfizer eyes long-term expansion across key therapeutic areas.
-
-
Pfizer's Strategic Bet on Bispecifics
Pfizer
Pfizer commits up to $6B for rights to SSGJ-707, a PD-1xVEGF bispecific, after in-depth due diligence in China. The asset is expected to complement Pfizer’s ADC portfolio and advance its oncology strategy.
-
-
Pfizer's Talzenna Label Bid Faces Setback
FDA
The FDA’s advisory committee unanimously rejected Pfizer’s proposal to expand Talzenna’s use for prostate cancer patients without HRR mutations, citing insufficient evidence from the TALAPRO-2 trial.
-
SK Bioscience Wins Key Patent Battle
SK Bioscience
SK Bioscience wins a key patent dispute against Pfizer in South Korea, enabling global exports of its 13-valent pneumococcal vaccine. The company plans expansion into Southeast Asia and Latin America while advancing next-gen vaccine R&D.
-
仁化县|
肇州县|
徐州市|
山阴县|
门源|
汶川县|
南丰县|
车险|
电白县|
德惠市|
淳化县|
黎川县|
汾西县|
岳阳县|
榆社县|
兴国县|
商洛市|
青浦区|
临桂县|
龙胜|
颍上县|
县级市|
宁晋县|
进贤县|
新龙县|
彩票|
云和县|
宜都市|
略阳县|
广平县|
吉林省|
德保县|
贵南县|
正蓝旗|
泗洪县|
泉州市|
登封市|
隆子县|
渭南市|
班戈县|
成安县|